deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT05011188

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

A Phase 1b/2 Study of FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Sponsor: Fortis Therapeutics, Inc.

Conditions Metastatic Castration-resistant Prostate Cancer Prostate Cancer
Interventions Blood Samples Enzalutamide FOR46 Pegfilgrastim
Updated 14 times since 2021 Last updated: Aug 25, 2025 Started: Jan 19, 2022 Primary completion: Jul 31, 2027 Completion: Jul 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Metastatic Castration-resistant Prostate Cancer and Prostate Cancer and is currently ongoing. Fortis Therapeutics, Inc. leads this study, which shows 14 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Jul 2022 · 4 months · monthly snapshot~Jul 2022 – ~Jul 2023 · 12 months · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jul 2025 · 9 months · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

14 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Sep 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jul 2025 — Sep 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Oct 2024 — Jul 2025 [monthly]

    Recruiting PHASE1/PHASE2

  5. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1/PHASE2

▶ Show 9 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  2. Oct 2023 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  3. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jul 2023 — Sep 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jul 2022 — Jul 2023 [monthly]

    Recruiting PHASE1_PHASE2

  6. Mar 2022 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Jan 2022 — Mar 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  8. Dec 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  9. Sep 2021 — Dec 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fortis Therapeutics, Inc.
  • Kyntra Bio
  • Rahul Aggarwal
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations